Bernard Vanhove
22Patents
3h-index
19Co-inventors
60Inventor score
Filing activity: Dec 26, 2001 → Sep 9, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9244059B2 | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease | Physics | 29 | Active |
| US7723482B2 | Anti-CD28 antibody | Chemistry; Metallurgy | 17 | Expired |
| US9447182B2 | Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates | Chemistry; Metallurgy | 4 | Active |
| US10364287B2 | Anti-CD28 humanized antibodies | Chemistry; Metallurgy | 3 | Active |
| US8785604B2 | Anti-CD28 humanized antibodies | Chemistry; Metallurgy | 3 | Active |
| US10428152B2 | Antibodies directed against CD127 | Physics | 2 | Active |
| US9562098B2 | Anti-CD28 humanized antibodies | Chemistry; Metallurgy | 2 | Active |
| US11279766B2 | Anti-SIRPa antibodies and their therapeutic applications | Physics | 2 | Active |
| US11440964B2 | Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody | Physics | 1 | Active |
| US9587023B2 | Recombinant monovalent antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US12258577B2 | Method effector cells using anti-CD127 antibodies for applications in cell therapy | Chemistry; Metallurgy | 0 | Active |
| US12091464B2 | Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1) | Chemistry; Metallurgy | 0 | Active |
| US8785138B2 | Monovalent ligands of the human CD28 receptor | Chemistry; Metallurgy | 0 | Active |
| US11098128B2 | Antibodies and polypeptides directed against CD127 | Chemistry; Metallurgy | 0 | Active |
| US11926671B2 | Antibodies and polypeptides directed against CD127 | Chemistry; Metallurgy | 0 | Active |
| US12371502B2 | Antibodies directed against CD127 | Physics | 0 | Active |
| US11365257B2 | Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) | Chemistry; Metallurgy | 0 | Active |
| US11884723B2 | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US11713356B2 | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer | Chemistry; Metallurgy | 0 | Active |
| US10689444B2 | Recombinant monovalent antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US12252546B2 | Anti-SIRPa antibodies and their therapeutic applications | Physics | 0 | Active |
| US12331115B2 | Uses of anti-SIRPg antibodies | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.